Galapagos Selects Pre-Clinical Candidate Drug for Cachexia 06 January 2009 Galapagos’ pre-clinical candidate G100192 has demonstrated successful Proof of Concept in animal studies.
AVI BioPharma Announces FDA Clearance of IND Applications for Clinical Trials of RNA Therapeutic Agents 31 December 2008 The Company has received verbal clearance from the FDA for its two lead products for Marburg and Ebola virus.